# Male infertility: the intracellular bacterial hypothesis

### M. Stojanov<sup>1</sup>, D. Baud<sup>1</sup>, G. Greub<sup>2</sup> and N. Vulliemoz<sup>3</sup>

1) Materno-fetal and Obstetrics Research Unit, Department Woman-Mother-Child, Lausanne University Hospital, 2) Institute of Microbiology, Lausanne University Hospital and University of Lausanne and 3) Fertility Medicine and Gynaecological Endocrinology Unit, Department Woman-Mother-Child, Lausanne University Hospital, Switzerland

#### Abstract

Infertility is a disease that affects one in seven couples. As male infertility affects approximately 30% of these couples with an unknown cause in half the cases, it represents a major public health concern. The classic treatment of male infertility involves intrauterine insemination, with modest outcome, and *in vitro* fertilization with intracytoplasmic sperm injection, which is known to be invasive and expensive, without treating the specific cause of infertility. Male fertility is mainly evaluated through a semen assessment where abnormal parameters such as concentration and motility can be associated with a decreased chance of conception. Infectious processes represent plausible candidates for male infertility. *Chlamydia trachomatis* is well known to cause female infertility through tubal damage but its role in male infertility remains controversial. The link between ureaplasmas/mycoplasmas and male infertility is also debatable. The potential negative impact of these bacteria on male fertility might not only involve semen parameters but also, as with *C. trachomatis*, include important physiological mechanisms such as fertilization processes that are not routinely assessed during infertility investigation. Basic research is important to help determine the exact effect of these bacteria on male fertility to develop targeted treatment and go beyond *in vitro* fertilization with intracytoplasmic sperm injection.

© 2018 The Author(s). Published by Elsevier Ltd.

Keywords: Chlamydia, male infertility, Mycoplasma, Ureaplasma Original Submission: 7 May 2018; Revised Submission: 7 August 2018; Accepted: 10 August 2018 Article published online: 22 August 2018

**Corresponding author:** N. Vulliemoz, Fertility Medicine and Gynaecological Endocrinology Unit, Department Woman-Mother-Child, Av. Pierre-Decker 2, CH-1011 Lausanne, Switzerland. **E-mail:** nicolas.vulliemoz@chuv.ch

M. Stojanov and D. Baud contributed equally to the present work.

#### Introduction

The World Health Organization (WHO) describes clinical infertility as a disease of the reproductive system defined by 'the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse' [1]. This disease, which affects one in seven couples, may be due to female factors, male factors, or both. A male infertility factor with abnormal semen parameters is found in approximately 50% of couples seeking infertility treatment [2]. The known causes of male infertility

include endocrine diseases, malignancies and genetic anomalies, but the cause remains unknown in 50% of cases. First-line evaluation of male fertility comprises a semen assessment. The criteria include volume, total sperm number, sperm concentration, vitality, progressive motility, total motility and morphology. In couples with infertility, the interpretation of a so-called abnormal semen assessment result (a parameter below the 5th centile compared with WHO reference values) remains difficult. For example, the clinical significance of a sperm concentration slightly under 15 million/mL versus markedly decreased (for example below 1 million/mL) implicates a very different prognosis for the couple regarding chances of conception.

Mild and severe male infertility are frequently used in the literature to describe an abnormal semen assessment but are purely descriptive and without clear definition and relationship to the aetiology, which is only found in approximately 50% of cases. Even when a diagnosis is confirmed, the treatment administered rarely targets the exact cause. Therefore, the vast

majority of men with male infertility are offered generic treatment based on the severity of the anomaly observed on the semen assessment, for example intrauterine insemination in mild situations and *in vitro* fertilization (IVF) with intracytoplasmic sperm injection for severe semen anomalies or when intrauterine insemination has failed. In vitro fertilization with intracytoplasmic sperm injection has revolutionized management of severe male infertility, but it does not treat the exact cause of infertility. It not only mainly involves the female partner, but is also invasive and expensive with increased risks of multiple births and their related complications. It is time to better understand the causes of male infertility so as to tailor treatments that target the aetiology and so increase the chance of natural pregnancy and decrease the need for invasive procedures.

# The infectious hypothesis

Adequate sperm production and function require a healthy urogenital tract to allow normal fertility. Inflammatory processes and bacterial infections have been associated with male infertility, but the exact mechanisms remain poorly understood [3]. The effect of an acute infection might not be as deleterious as a chronic infection where a silent/asymptomatic inflammatory process might have long-lasting negative impact on sperm function, on spermatogenesis, and on permeability of the vas deferens and/or ejaculatory duct. Pathogens that chronically colonize the male urogenital tract could have a negative impact on fertility by affecting the parameters of the semen assessment (count or motility) or even by inducing apoptosis [4]. In that regard, microorganisms such as Chlamydia trachomatis, ureaplasmas and mycoplasmas represent interesting candidates to understand a link between infection and male infertility.

## Chlamydia trachomatis

*Chlamydia trachomatis* is the most common sexually transmitted disease, affecting millions of men and women annually, but the true prevalence of *Chlamydia* is difficult to determine because the infection is asymptomatic in up to 85%–90% of infected individuals [5].

Acute chlamydial infection in men causes urethritis, epididymitis (-orchitis) and prostatitis [6]. Inflammation of the epididymis can induce infertility through sperm tract obstruction, especially when both testes are infected [7]. The evidence of a potential deleterious effect of *Chlamydia* on male fertility comes from animal models of infection and *in vitro* experiments. Destruction of male germ cells and Sertoli cells was observed in a murine model of *Chlamydia* infection [8]. Electron microscopy studies have demonstrated that *Chlamydia* can interact with sperm cells and can induce apoptosis through lipopolysaccharide [9,10]. The mechanism involves interaction of lipopolysaccharide with sperm cell CD14 receptor and consequently release of reactive oxygen species that can induce apoptosis through caspases [11]. Motility, an important parameter of male fertility, has also been shown to be altered by *Chlamydia* [4]. Interestingly, another *Chlamydia*-related bacterium, *Waddlia chondrophila*, which was strongly associated with miscarriage in humans, was able to adhere and penetrate inside human spermatozoa and decrease viability, as well as mitochondrial membrane potential [12].

An alternative impact of *Chlamydia* on fertility might involve a state of subclinical chronic infection. Upon exposition to stressors, such as increased interferon- $\gamma$  levels or antibiotics, bacteria might form aberrant bodies that represent a persistent, non-replicative and non-infectious form of *Chlamydia* [13]. When the stressors are removed, *Chlamydia* can re-enter a normal life cycle and recover its infectious potential.

Retrospective epidemiological data have failed to demonstrate that past Chlamydia infection is associated with altered sperm characteristics [14]. In a study where 284 male partners of infertile couples were screened for C. trachomatis infection, there was no statistical difference between infected and noninfected male partners in terms of semen parameters and function [15]. In another study including 104 asymptomatic infertile men attending a Tunisian infertility clinic, detection of C. trachomatis in semen was not associated with abnormal classic semen parameters [16]. These results are in contrast with a study involving 627 sperm donors, in which the Chlamydia-positive group had significantly reduced morphology (14.4%), volume (6.4%), concentration (8.3%), motility (7.8%) and velocity (9.3%) compared with the control group [17]. Moreover, an association between C. trachomatis IgG antibodies and subfertility (defined as time to conceive  $\geq$  12 months) was observed in Finland [18]. Similarly, in couples referred to a Swedish infertility clinic, decreased pregnancy rates were correlated with the presence of C. trachomatis IgG antibodies in the male partner independently of tubal infertility factor [19]. However, presence of C. trachomatis IgG in the male partner was not associated with an abnormal parameter of the semen assessment. These data suggest that the potential detrimental effect of C. trachomatis on male fertility might not involve the semen parameters assessed routinely, but may potentially affect attachment of the sperm to the oocyte or later steps of cell division or implantation. Therefore other mechanisms involved in sperm function might give clues on how C. trachomatis might affect male fertility. Acrosome reaction, which represents an

© 2018 The Author(s). Published by Elsevier Ltd, NMNI, 26, 37-41

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Download English Version:

# https://daneshyari.com/en/article/10218758

Download Persian Version:

https://daneshyari.com/article/10218758

Daneshyari.com